Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical 2% tofacitinib for non-pustular palmoplantar psoriasis
RBR-8x8nmb4Phase 3Not yet recruiting
- Sponsor
- Unioeste
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tofacitinib in palmoplantar psoriasis (3 arms), sponsored by Unioeste. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
03
Conditions
palmoplantar psoriasis
Beyond the preview
Go deeper on RBR-8x8nmb4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-8x8nmb4.